Pfizer Goes On Offense With Celebrex: Plans Trial In High-Risk Patients

Placebo-controlled study would look at 4,000 high-risk osteoarthritis patients to test theory that Celebrex will reduce cardiovascular events, Pfizer declares. The company will discuss the trial's design with FDA and expects to initiate enrollment in 2005.